Nephroprotective action of Renin-Angiotensin-Aldosterone system blockade in chronic kidney disease patients: The landscape after ALTITUDE and VA NEPHRON-D trails

Journal of Renal Nutrition

Volumn 25, Issue 2, 2015, Pages 194-200

  Rutkowski, Boleslaw ^a   Tylicki, Leszek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DRUG EFFECTS; HUMAN; NEPHRON; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; NEPHRONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84925119896     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2014.10.026     Document Type: Review

References (67)

1. Lavoie J.L., Sigmund C.D. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144:2179-2183.
2. Wolf G., Butzmann U., Wenzel U. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003, 93:p3-p13.
3. Arima S., Kohagura K., Abe M., Ito S. Mechanisms that control glomerular hemodynamics. Clin Exp Nephrol 2001, 5:55-61.
4. Ruiz-Ortega M., Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997, 52:1497-1510.
5. Wolf G., Kalluri R., Ziyadeh F.N., Neilson E.G., Stahl R.A. Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians 1999, 111:357-364.
6. Wolf G., Killen P.D., Neilson E.G. Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991, 2:219-227.
7. Baricos W.H., Cortez S.L., el-Dahr S.S., Schnaper H.W. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995, 47:1039-1047.
8. Gesualdo L., Ranieri E., Monno R., et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999, 56:461-470.
9. Giachelli C.M., Pichler R., Lombardi D., et al. Osteopontin expression inangiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994, 45:515-524.
10. Wolf G., Schneider A., Helmchen U., Stahl R.A. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998, 6:112-120.
11. Wolf G., Ziyadeh F.N., Thaiss F., et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997, 100:1047-1058.
12. Jaimes E., Galceran J., Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998, 54:775-784.
13. Yamada T., Horiuchi M., Dzau V. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996, 93:156-160.
14. Ohnaka K., Numaguchi K., Yamakawa T., Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 2000, 35:68-75.
15. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int 2004, 66:1-9.
16. Sun Y., Zhang J., Zhang J.Q., Ramires F.J. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000, 35:1078-1084.
17. Ullian M.E., Schelling J.R., Linas S.L. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992, 20:67-73.
18. Iglarz M., Touyz R.M., Viel E.C., Amiri F., Schiffrin E.L. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotension system. Am J Hypertens 2004, 17:597-603.
19. Brown N.J., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336-344.
20. Nguyen G., Muller D.N. The biology of the (pro)renin receptor. J Am Soc Nephrol 2010, 21:18-23.
21. Taal M., Brenner B. Renoprotective benefits of ras inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57:1803-1817.
22. Schmieder R.E., Ruilope L.M., Barnett A.H. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 2012, 24:569-580.
23. Delyani J.A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000, 57:1408-1411.
24. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-E8.
25. Morganti A., Lonati C. Aliskiren: the first direct renin inhibitor available for clinical use. J Nephrol 2011, 24:541-549.
26. Parving H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner R. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
27. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
28. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
29. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
30. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
31. Ruggenenti P., Perna A., Gheradi G., et al. Renoprotective properties of ace-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
32. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
33. Barnett A.H., Bain S.C., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
34. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
35. Viberti G., Mogensen C.E., Groop L.C., Pauls J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275-279.
36. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
37. Tylicki L., Rutkowski P., Renke M., Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Am J Nephrol 2002, 22:356-362.
38. Gansevoort R., De Zeeuw D., De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system ?. Kidney Int 1994, 45:861-867.
39. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.
40. Lizakowski S., Tylicki L., Renke M., et al. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. Int Urol Nephrol 2013, 44:1763-1770.
41. Tylicki L., Lizakowski S., Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol 2012, 25:900-910.
42. Shiigai T., Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 2001:477-483.
43. Sarafidis P.A., Ruilope L.M. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. Kidney Int 2013, 85:536-546.
44. Fogo A.B. Regression lines in chronic kidney disease. J Am Soc Nephrol 2003, 14:2990-2991.
45. Peters H., Border W., Noble N. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54:1570-1580.
46. Adamczak M., Gross M., Krtil J., et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14:2833-2842.
47. Boffa J.J., Lu Y., Placier S., Stefanski A., Dussaule J.C., Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003, 14:1132-1144.
48. Ma L.J., Nakamura S., Whitsitt J.S., Marcantoni C., Davidson J.M., Fogo A.B. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000, 58:2425-2436.
49. Palla R., Panichi V., Finato V., et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994, 14:35-43.
50. Weinberg M., Weinberg A., Cord R., Zappe D. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2002, 2(Suppl. 1):S196-S198.
51. Haas M., Leko-Mohr Z., Erler C., Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002, 40:458-463.
52. Tylicki L., Renke M., Rutkowski P., et al. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study. Scand J Urol Nephrol 2008, 42:381-388.
53. Taal M., Brenner B. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens 2002, 11:377-381.
54. Bakris G.L. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int 2010, 78:546-549.
55. Rutkowski P., Tylicki L., Renke M., Korejwo G., Zdrojewski Z., Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004, 43:260-268.
56. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
57. Tylicki L., Lizakowski S., Rutkowski P., et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade-which is the best?. Kidney Blood Press Res 2012, 36:335-343.
58. Chrysostomou A., Pedagogos E., MacGregor L., Becker G. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
59. Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
60. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
61. Tylicki L., Rutkowski P., Renke M., et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008, 52:486-493.
62. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
63. de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013, 369:1960-1962.
64. Lizakowski S., Tylicki L., Rutkowski P., Rutkowski B. Dual blockade of the renin-angiotensin-aldosterone system in renal disease: what is the future? Authors' reply. Pol Arch Med Wewn 2014, 124:73-74.
65. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
66. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369:1892-1903.
67. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.